Compare ALZN & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALZN | ISPC |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 3.8M |
| IPO Year | 2021 | 2020 |
| Metric | ALZN | ISPC |
|---|---|---|
| Price | $1.03 | $5.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $28.00 | N/A |
| AVG Volume (30 Days) | 54.4K | ★ 23.1M |
| Earning Date | 03-11-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.99 | ★ 87.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,928,998.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.84 | $0.10 |
| 52 Week High | $8.22 | $6.77 |
| Indicator | ALZN | ISPC |
|---|---|---|
| Relative Strength Index (RSI) | 43.13 | 76.40 |
| Support Level | $1.03 | $0.37 |
| Resistance Level | $1.21 | $6.77 |
| Average True Range (ATR) | 0.07 | 0.66 |
| MACD | 0.02 | 0.26 |
| Stochastic Oscillator | 35.00 | 76.11 |
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.